Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SRPT message board posts where the ticker symbol SRPT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SRPT SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001564590-18-015793 (34 Act)  Size: 4 MB
2018-06-19 001-14895
18906436
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-037075 Size: 8 KB
2018-06-11
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001209191-18-037072 Size: 3 KB
2018-06-11
8-K  Documents Current report, item 5.07
Acc-no: 0001564590-18-015160 (34 Act)  Size: 62 KB
2018-06-06 001-14895
18884263
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033112 Size: 9 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033111 Size: 9 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033109 Size: 9 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033108 Size: 9 KB
2018-05-24
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001193125-18-150787 (34 Act)  Size: 19 MB
2018-05-03 001-14895
18803689
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-010662 (34 Act)  Size: 10 MB
2018-05-03 001-14895
18803683
More SRPT SEC Filings


Related news from
Fri, 22 Jun 2018
19:28:06 +0000
Why Investors Are in a Frenzy over Sarepta Stock in June
On June 19, Sarepta Therapeutics (SRPT) announced positive preliminary results from its phase one part 2a gene therapy micro dystrophin trial on treating patients with Duchenne muscular dystrophy (or DMD) from the first three children dosed. DMD generally affects boys, and death typically occurs before age 30 in DMD patients. In all three patients, biopsies done on the 90th day showed robust micro dystrophin expression in muscle as measured by all methods.
Fri, 22 Jun 2018
19:28:05 +0000
Analyzing Sarepta’s Agreement with Myonexus Therapeutics
Sarepta Therapeutics (SRPT) and Myonexus Therapeutics entered into a warrant to purchase Myonexus common stock on May 3. This agreement gives Sarepta the exclusive option to acquire Myonexus. Myonexus completes a successful biopsy analysis on all the patients in cohort two capable of providing a biopsy at the end of 60 days of Myonexus’s phase one and two clinical trial of MYO-101.
Fri, 22 Jun 2018
19:28:05 +0000
A Look at Sarepta’s Exondys 51 Commercialization Efforts
By applying its proprietary platform technologies, Sarepta Therapeutics (SRPT) is able to target a range of diseases and disorders. The company’s first product on the US market, the Exondys 51 injection, received accelerated approval from the US FDA in September 2016. The injection is targeted for treating Duchenne muscular dystrophy (or DMD).
Fri, 22 Jun 2018
19:28:04 +0000
How Has Sarepta Therapeutics Performed Financially?
The company incurred costs of sales of $5.6 million in Q1 2018 as compared with $223,000 in Q1 2017. Sarepta Therapeutics incurred research and development expenses of $46.2 million in Q1 2018 as compared with $29.1 million in Q1 2017. The selling, general, and administrative expenses incurred by the company also grew from $26.2 million in Q1 2017 to $43.3 million in Q1 2018.
Fri, 22 Jun 2018
19:28:04 +0000
Analysts Are Bullish on Sarepta Therapeutics in June
Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company with a focus on developing unique RNA targeted therapies, gene therapy, and other genetic medicine approaches for treating rare neuromuscular diseases. In the last three days, Sarepta stock has risen by more than 50% on preliminary results from its Duchenne muscular dystrophy (or DMD) study. In June, 15 of the total 17 analysts covering Sarepta Therapeutics have given it a “buy” or a higher rating, while two analysts have given the stock a “hold” rating.
Fri, 22 Jun 2018
19:28:04 +0000
How Sarepta’s Cash Flows Are Trending
Sarepta Therapeutics (SRPT) spent $35.7 million on operating activities in Q1 2018. In comparison, the company spent $57.9 million in operating activities in Q1 2017. In Q1 2018, Sarepta Therapeutics spent $14.3 million on investing activities. It generated $210 million from investing activities in Q1 2017. Sarepta spent $12.2 million on the purchase of property and equipment in Q1 2018 as compared with $4.5 million in Q1 2017. In Q1 2017 the company received $90.7 million from maturities of available for sale securities and restricted investment. ...
Fri, 22 Jun 2018
18:17:00 +0000
Analysts’ Recommendations for PTC Therapeutics in June
In June, the Committee for Medicinal Products for Human Use (or CHMP) of the European Medicines Agency (or EMA) recommended a positive opinion for the expansion of Translarna’s indication to include ambulatory children between the ages of two and five years with nonsense mutation Duchenne muscular dystrophy. The CHMP recommendation was based on data from the PTC Therapeutics Study 030.
Fri, 22 Jun 2018
13:20:00 +0000
Big Biotech Stock Pops and Drops This Week
Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.
Fri, 22 Jun 2018
12:41:12 +0000
DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus
Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.
Thu, 21 Jun 2018
15:12:00 +0000
FAANG Stocks Are Being Nailed
After enjoying some great trading action over the past week we are now seeing a very heavy bout of profit taking. The momentum names that the traders have been favoring lately such as Netflix , iQIYI and Sarepta are being hit and it is spilling over to a wide variety of names.
Thu, 21 Jun 2018
12:26:00 +0000
Is Sarepta Therapeutics Stock Headed to Over $200 a Share?
Wall Street thinks Sarepta Therapeutics is still a bargain even after its shares have more than doubled in value this year.
Thu, 21 Jun 2018
12:00:00 +0000
Trending: Technology Sector Surges to Record Highs Despite Trade Jitters
Investors have bought into the technology sector with fervor as markets enjoyed a brief period of tranquility just before politicians resumed their belligerent rhetoric.
Wed, 20 Jun 2018
19:23:00 +0000
Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back
Sarepta shares were up $10.23 -- or 7.11% -- to $154.16 in mid-afternoon trading Wednesday after adding 36.8% Tuesday after the firm disclosed impressive test results for its new gene therapy designed to cure a rare form of muscular dystrophy. , which took a 30.6% hit Tuesday on Sarepta's announcement, regained some of its losses and rebounded 6.26% to $35.32 as of Wednesday afternoon. Zhong anticipates Sarepta will continue to rally, as investors are excited about the quality of findings on the gene therapy's effectiveness, as well as about the drug's market potential.
Wed, 20 Jun 2018
17:47:29 +0000
This Biotech Is Cratering On Sarepta's Success — But Could Be 'Superior'
Solid Biosciences plunged Wednesday on high volume after rival Sarepta Therapeutics reported strong data for its Duchenne muscular dystrophy treatment.
Wed, 20 Jun 2018
14:55:02 +0000
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Wed, 20 Jun 2018
14:00:02 +0000
Company News For Jun 20, 2018
Companies in the news are: T,FMI,COTV,SRPT
Wed, 20 Jun 2018
12:48:05 +0000
Sarepta shares rocket 40% on promising early results for DMD gene therapy
Sarepta Therapeutics Inc. shares skyrocketed 37.8% in Tuesday trade after the company released promising early results from a gene therapy program being developed for the rare degenerative disease Duchenne muscular dystrophy. Tuesday marked the stock’s second-largest percentage gain in over 20 years. Its largest-ever percentage gain came in September 2016, when Sarepta’s (SRPT) first drug was approved by the Food and Drug Administration.
Wed, 20 Jun 2018
12:36:56 +0000
Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 19) AngioDynamics, Inc. (NASDAQ: ANGO ) Array Biopharma Inc (NASDAQ: ...
Wed, 20 Jun 2018
12:32:12 +0000
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
Wed, 20 Jun 2018
12:00:00 +0000
Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Caladrius Biosciences
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / It was a day of big gains for biotech stocks Sarepta Therapeutics and Caladrius Biosciences on Tuesday. Sarepta soared almost 37% on positive interim data on ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is one of the brightest and most generous groups you will ever come across. While I firmly believe everyone has something to contribute to the collective wisdom, this is pretty much a left-brain group. Facts, evidence, and reasoned argument will earn you respect, even if some disagree with you." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards